ERNA Latest Press Releases

-- October 22, 2026 --

Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New 'What This Means' Segment Globe Newswire 8:53 AM

-- October 12, 2026 --

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series Globe Newswire 4:05 PM

-- October 6, 2026 --

Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center Globe Newswire 8:55 AM

-- October 1, 2026 --

Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic Globe Newswire 9:20 AM

-- September 30, 2026 --

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND Globe Newswire 8:32 AM

-- September 29, 2026 --

Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy Globe Newswire 9:15 AM

-- September 17, 2026 --

Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors Globe Newswire 8:42 AM

-- September 15, 2026 --

Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing Globe Newswire 8:42 AM

-- September 14, 2026 --

Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 9:05 AM

-- August 27, 2026 --

JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs ACCESS Newswire 9:01 AM

Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference Globe Newswire 9:01 AM

-- August 10, 2026 --

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage Globe Newswire 9:01 AM

-- July 24, 2026 --

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies Globe Newswire 9:20 AM

-- July 15, 2026 --

Three Biotechs Deliver Catalysts to Watch Globe Newswire 10:42 AM

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry Globe Newswire 7:50 AM

-- July 14, 2026 --

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 Globe Newswire 9:01 AM

-- June 25, 2026 --

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients Globe Newswire 9:15 AM

-- June 17, 2026 --

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study Globe Newswire 8:47 AM

-- June 9, 2026 --

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer Globe Newswire 8:41 AM

-- May 27, 2026 --

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development Globe Newswire 8:11 AM

Market Data Delayed 15 Minutes